Association Between Pre-Ablation Glycemic Control and Outcomes Among Patients With Diabetes Undergoing Atrial Fibrillation Ablation.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
08 2019
Historique:
received: 28 02 2019
revised: 16 05 2019
accepted: 17 05 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 24 10 2020
Statut: ppublish

Résumé

The aim of this study was to investigate the impact of improved glycemic control on atrial fibrillation (AF) recurrence rates after ablation. Diabetes is associated with increased rates of AF. The impact of improved pre-ablation glycemic control remains unknown. The 12-month pre-ablation trends in glycemic control were studied in 298 patients with diabetes undergoing AF ablation. Recurrence data were obtained during a mean follow-up period of 25.92 ± 20.26 months post-ablation. Higher glycated hemoglobin (HbA The trend in glycemic control prior to ablation predicts arrhythmia recurrence after ablation. A multidisciplinary approach to reduce HbA

Sections du résumé

OBJECTIVES
The aim of this study was to investigate the impact of improved glycemic control on atrial fibrillation (AF) recurrence rates after ablation.
BACKGROUND
Diabetes is associated with increased rates of AF. The impact of improved pre-ablation glycemic control remains unknown.
METHODS
The 12-month pre-ablation trends in glycemic control were studied in 298 patients with diabetes undergoing AF ablation. Recurrence data were obtained during a mean follow-up period of 25.92 ± 20.26 months post-ablation.
RESULTS
Higher glycated hemoglobin (HbA
CONCLUSIONS
The trend in glycemic control prior to ablation predicts arrhythmia recurrence after ablation. A multidisciplinary approach to reduce HbA

Identifiants

pubmed: 31439289
pii: S2405-500X(19)30392-5
doi: 10.1016/j.jacep.2019.05.018
pii:
doi:

Substances chimiques

Glycated Hemoglobin A 0
hemoglobin A1c protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

897-903

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Eoin Donnellan (E)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Philip Aagaard (P)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mohamed Kanj (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Wael Jaber (W)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Mohamed Elshazly (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Michael Hoosien (M)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Bryan Baranowski (B)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Ayman Hussein (A)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Walid Saliba (W)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Oussama Wazni (O)

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address: waznio@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH